SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing a surge in community interest driven by its technological focus on quantum-resistant security and its potential role in real-world asset (RWA) tokenization. Investors are actively debating the long-term institutional utility of the protocol, with many pointing to recent ecosystem developments and potential regulatory catalysts as signs of an upcoming turnaround.

Ciena Corp. is a network technology company, which engages in the provision of hardware, software, and services to network operators, as well as enabling enhanced network capacity, service delivery, and automation. It operates through the following segments: Networking Platforms, Platform Software and Services, Blue Planet Automation Software and Services, and Global Services. The Networking Platforms segment consists of converged packet optical and packet networking portfolios. The Platform Software and Services segment provides analytics, data, and planning tools to assist customers in managing its networking platforms products. The Blue Planet Automation Software and Services segment enables customers to implement large-scale software and IT-led OSS transformations by transforming legacy networks into service ready networks. The Global Services segment offers a broad suite of value-added services. The company was founded by Patrick H. Nettles and Kevin Brian Kimberlin in 1992 and is headquartered in Hanover, MD.

CIENA Corp.

Ciena is gaining strong momentum as investors increasingly view the company as a critical backbone for AI-driven data center infrastructure and high-speed network expansion. The community is actively debating the stock's parabolic trajectory and aggressive valuation, with many traders closely watching for technical signals while balancing bullish long-term thesis on photonics against potential volatility risks.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF (VTI) is trending as retail investors engage in intense debates regarding the potential impact of escalating geopolitical tensions in the Middle East and domestic political instability on the broader US markets. Community discussion remains heavily polarized, with many users weighing the risks of prolonged market volatility against the conviction that a simplified, long-term buy-and-hold strategy remains the most effective defense against current macro uncertainty.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph (HBAR) is currently generating buzz as investors monitor potential regulatory catalysts like the CLARITY Act, which some believe could provide institutional clarity and trigger a significant price re-rating. While retail sentiment remains cautious and polarized over token dilution and price performance, the community is closely tracking institutional accumulation, recent exchange listings, and the integration of Hedera's ledger technology by major enterprise partners.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently the center of active community debate as shareholders press for strategic changes, driven by activist pressure from Shah Capital and speculation regarding leadership stability following recent executive departures. Investors are closely monitoring the stock for signs of a potential buyout or major partnership, while sentiment remains polarized between those anticipating a volatility-driven breakout and others frustrated by the stock's persistent price suppression.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is currently drawing significant investor attention as momentum builds around its role in the defense and aerospace supply chain, highlighted by recent high-profile contract wins and significant insider debt-to-equity conversions. The community is actively debating the company's long-term potential as a critical infrastructure provider for entities like SpaceX and the Department of Defense, while closely watching for further partnership updates and financial milestones.

Shift4 Payments, Inc. is an independent provider, which engages in the provision of payment acceptance and payment processing technology solutions in the U.S. based on total volume of payments processed. It operates through the U.S. and International geographical segments. The company was founded by Jared Isaacman in 1999 and is headquartered in Center Valley, PA.

Shift4 Payments Inc - Ordinary Shares - Class A

Shift4 Payments is seeing active community debate as investors weigh strong fundamental growth and insider buying against concerns over debt levels, recent executive departures, and intense competition in the fintech sector. While bulls highlight the potential for long-term expansion and a large-scale share repurchase program, bears are pointing to inconsistent earnings guidance and the risks associated with the company's aggressive M&A strategy.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is surging as gold prices climb toward record levels, fueled by a potent mix of safe-haven demand, central bank buying, and geopolitical instability. Market participants are actively tracking the stock's significant momentum, with many discussing its potential to act as a leveraged play on golds long-term bull case while monitoring dividend trends and share buyback strategies.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is seeing renewed bullish sentiment as investors eye the upcoming Game Developers Conference (GDC) for potential breakthroughs in AI and engine technology, while recent analyst upgrades have shifted the narrative from a bearish stance to a more cautious but optimistic outlook on its valuation. The community is actively debating the stock's potential for a short squeeze, fueled by high short interest and expectations that technical catalysts could finally reverse its recent downward trend.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is trending ahead of its upcoming earnings report as investors weigh strong premium demand against headwinds from rising jet fuel costs and operational disruptions. The community is actively debating the stock's valuation, with many traders analyzing call and put positioning to determine if the current price level marks a sustainable top or a consolidation before further momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The agency’s assessment was based on the company’s Phase 2 data package.</li><li>The FDA supported the use of Clinical Dementia Rating Scale-Sum of Boxes, a scale used to determine dementia severity.</li><li>INmune will enroll about 300 participants over nine months to confirm efficacy before expanding to a 1,000-patient Phase 3 trial.</li></ul>INmune Bio, Inc (INMB) stock gave up some of its pre-market gains to trade 3% higher on Thursday morning, after the company said it has received official U.S. Food and Drug Administration (FDA) meeting minutes confirming regulatory alignment on its integrated Phase 2b/3 development plan for XPro1595, a potential therapy for early Alzheimer’s disease.The FDA supported INmune Bio’s precision medicine strategy, which uses a trial design to identify patients whose inflammatory biomarker profiles are tied to soluble tumor necrosis factor (TNF) signalling, the treatment’s biological target.The agency’s assessment was based on the company’s Phase 2 data package, which included cognitive and biomarker findings.“XPro1595 represents a differentiated approach to Alzheimer’s disease, based on precision patient selection and selective immune modulation, with a favorable safety profile that included zero cases of ARIA in our Phase 2 study,” said David Moss, INmune Bio’s CEO.<h2 class="st-heading-2">FDA Approval Details</h2>The FDA supported the use of the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) as the primary endpoint, a scale used to assess dementia severity and track progression. It also did not object to INmune Bio’s plan to enroll patients identified by key inflammation-related biomarkers linked to the drug’s target.The company said that the Phase 2b part will feature a nine-month evaluation period to build the clinical foundation for a subsequent Phase 3 study. INmune will enroll about 300 participants over nine months to confirm efficacy before expanding to a 1,000-patient Phase 3 trial lasting 18 months.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned’ bullish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/INMB_jpg_241e60ecf9.webp" alt="INMB.jpg">One user noted a tepid market reaction and said that it was an “excellent time to add” the stock to their portfolio.<stembedurl>https://stocktwits.com/10baggerPete/message/644778292</stembedurl>Another user said the company was “moving in the right direction.”<stembedurl>https://stocktwits.com/bioinvestorrr/message/644769951</stembedurl><a href="https://stocktwits.com/symbol/INMB">INMB shares</a> have declined around 0.6% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-china-retail-sales-slump-in-january/cZRTn3fR4rK">Tesla’s China Retail Sales Slump 45% In January: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial?

The FDA meeting minutes suggest INmune Bio’s late-stage Alzheimer’s trial design is on track.

Equity

INmune Bio (NASDAQ:INMB) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised INmune Bio from a "sell" rating to a "hold" rating in a research note on Sunday...

Praetorian PR LLC Sells 863,000 Shares of INmune Bio, Inc. $INMB

Praetorian PR LLC lowered its stake in INmune Bio, Inc. (NASDAQ:INMB - Free Report) by 99.3% in the second quarter, according to the company in its most recent disclosure with the Securities and...

INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

INmune Bio (INMB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

INmune Bio (INMB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

INmune  slides again as Scotiabank, RJ cut ratings after Alzheimer’s drug miss

Investing.com --  INmune Bio  (NASDAQ:INMB) shares fell another 6% to about $2.17 on Tuesday after brokerages downgraded the stock, saying failure of the company’s experimental Alzheimer’s drug XPro in a mid‑stage trial sharply weakens its investment case.

INmune Bio Inc. (INMB) on Monday said that its experimental drug XPro did not show any effects in the intent-to-treat population in a mid-stage study evaluating its effectiveness in early Alzheimer’s Disease (AD) with biomarkers of inflammation.INmune’s stock fell about 59% in morning trade at the time of writing.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/30/3107380/0/en/INmune-Bio-Reports-Key-Findings-from-Phase-2-MINDFuL-Trial-of-XPro-in-Early-Alzheimer-s-Disease.html">trial </a>enrolled 208 participants with early-stage Alzheimer’s to asses the drug’s potential in slowing cognitive decline by tackling neuroinflammation.The primary endpoint of the study was a change in cognition over 6 months on the Early Mild Alzheimer’s Cognitive Composite (EMACC). EMACC is a tool used in clinical trials and research to assess cognitive changes in individuals with early or mild Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI).The primary endpoint was not met in the intent-to-treat population.However, changes in clinical measures of cognition, behavior, and an AD-related biomarker demonstrated a benefit in a subpopulation of 100 early Alzheimer's patients with inflammation biomarkers who were treated with XPro, compared to patients treated with placebo, the company said.CEO RJ Tesi said that the findings lay the foundation for advancing XPro as a “promising treatment option” for Alzheimer’s.XPro treatment was safe and well-tolerated, the company added.<a href="https://stocktwits.com/symbol/INMB">INmune</a> now intends to schedule an end-of-mid-stage meeting with the U.S. Food and Drug Administration (FDA) in the last quarter of 2025 to define the path forward for a pivotal trial to support XPro approval in early Alzheimer’s.Despite the drop in INMune stock during Monday’s trading session, retail sentiment around the stock is trending in the ‘extremely bullish’ territory on Stocktwits.INMB stock is down by about 53% this year and by about 74% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/moderna-flu-vaccine-show-positive-results-in-late-stage-trial/chmZitPRR72">Moderna Stock Surges Pre-Market As Flu Vaccine Shows Positive Results In Late-Stage Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial

The primary endpoint of the study was not met in the intent-to-treat population, the company said. 

INmune Bio stock plummets after mixed Phase 2 Alzheimer’s trial results

Investing.com --  INmune Bio  Inc. (NASDAQ:INMB) stock fell 60% in pre-market trading Monday after the company reported mixed results from its Phase 2 MINDFuL trial of XPro in early Alzheimer’s disease patients.

INmune Bio Inc. (INMB) on Friday said that it entered into securities purchase agreements with two healthcare-focused institutional investors for the purchase and sale of 3 million shares of its common stock.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/27/3106725/0/en/INmune-Bio-Inc-Announces-Approximately-19-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html">said</a> that it would sell 3 million shares of its common stock in a registered direct offering at a purchase price of $6.30 per share. The proceeds from the offering are expected to be about $19 million, excluding costs such as fees to the placement agency Alliance Global Partners.<a href="https://stocktwits.com/symbol/INMB">INmune Bio</a> said that it intends to use the proceeds from the offering for working capital purposes and general corporate purposes.The closing of the offering is expected to occur on or about June 20.INMB shares are down 19% on Friday afternoon.&nbsp;On Stocktwits, retail sentiment around INmune Bio is unmoved within the ‘extremely bullish’ territory over the past 24 hours, while retail chatter stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_27_at_2_24_21_PM_png_cb3ab03d42.webp" alt="INMB's Sentiment Meter and Message Volume as of 2:25 p.m. ET on June 27, 2025 | Source: Stocktwits" width="625" height="64"><figcaption>INMB's Sentiment Meter and Message Volume as of 2:25 p.m. ET on June 27, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the company is headed to a year-long downtrend.<stembedurl>https://stocktwits.com/CharlesIV/message/619287462</stembedurl>Another user opined that a stock offering before data results is “sketchy.”<stembedurl>https://stocktwits.com/EddieGon/message/619286742</stembedurl>INmune Bio is slated to present topline results from its mid-stage Alzheimer’s trial, the MINDFuL study, on Monday. The trial is testing its lead drug candidate XPro in patients with mild cognitive impairment or Alzheimer’s disease with brain inflammation.The MINDFuL study will compare XProTM to placebo to find out whether XPro affects memory, functioning, and behavior. The study will also evaluate whether XPro is safe and tolerable.INMB stock is up by 9% this year and down by about 41% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gilead-stock-rises-on-us-supreme-court-ruling-in-favor-of-health-insurers-covering-preventive-care/chmWPN2RRe5">Gilead Stock Rises On US Supreme Court Ruling In Favor Of Health Insurers Covering Preventive Care</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

INmune Bio Stock Slumps On 3M Share Offering Ahead Of Mid-stage Trial Data, But Retail Remains Bullish 

The company said that it would sell 3 million shares of its common stock in a registered direct offering at a purchase price of $6.30 per share.

INmune Bio saw its stock surge 75% in after-hours trading Thursday after disclosing plans to unveil topline results from its Phase 2 Alzheimer’s trial on Monday.The company will present findings from its MINDFuL study, a placebo-controlled trial testing its lead drug candidate XPro in patients showing early signs of Alzheimer’s.&nbsp;The study participants consisted of 208 patients diagnosed with mild cognitive impairment or mild Alzheimer's disease.&nbsp;The average age of the participants was 72 years. In all of the participants, biomarkers of inflammation were present.&nbsp;The inflammatory biomarkers observed were elevated C-reactive protein levels, along with increased ESR and higher HbA1c values and genetic markers such as the APOE ε4 allele.&nbsp;Participants were randomized 2-to-1 to receive weekly doses of XPro or a placebo for just under six months.The main goal of the study is to assess cognitive change using a custom measurement tool called the early and mild Alzheimer's cognitive composite&nbsp;(EMACC), designed to detect subtle shifts in early-stage Alzheimer’s.&nbsp;Previous data showed the EMACC aligns well with other standard assessments like MMSE and CDR-SB.The company reported that over two-thirds of participants carried the APOE ε4 gene, and nearly two-thirds qualified through more than one biomarker.&nbsp;Roughly 72% of patients screened for the trial were not enrolled, mostly due to more advanced disease.In addition to cognitive scoring, the study includes secondary measures such as evaluations of daily living, neuropsychiatric symptoms, and biological markers.XPro is part of the company’s broader immune-targeting drug platform, which focuses on conditions believed to stem from chronic inflammation.&nbsp;<a href="https://stocktwits.com/symbol/INMB">INmune</a> is also exploring XPro for use in depression, alongside other programs for cancer and rare skin disorders.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 344% surge in 24-hour message volume.One user said that the timing of the announcement indicated confidence from the company, noting that results slated for early Monday were unlikely to disappoint.<stembedurl>https://stocktwits.com/winefan/message/619189685</stembedurl>They also referenced commentary from&nbsp;“pharma bro”&nbsp;Martin&nbsp;Shkreli, who previously stated that if the drug proves effective, the stock could surge dramatically, possibly even reaching triple-digit levels.Another user noted the pre-market Monday scheduling as a potentially encouraging signal but said they wouldn’t celebrate until the actual data is released.<stembedurl>https://stocktwits.com/BoilerKing/message/619167991</stembedurl>The stock has risen 27.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

INmune Bio Skyrockets After-Hours On Alzheimer’s Trial Buzz; Retail Bulls Bet Big Before Data Reveal Next Week

INmune is also developing XPro for treatment-resistant depression and exploring other immune-driven conditions like cancer and rare skin disorders.

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.

INmune Bio Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

INMB
INmune Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest INMB News

INMBINmune Bio Inc